Business
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking to a range of pharma and biotech executives and investors last week.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The company plans to use the money to boost its drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
Hal Barron, the man who guided the reinvigoration of the pharmaceutical direction at GSK, is departing the company to be the CEO of Altos Labs.
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
The company’s co-Founder, President and CEO Dr. P. Peter Ghoroghchian, took time to discuss the company and the financing round with BioSpace.
Funds are always flowing in the life science industry. Here’s where the money’s headed this week.
Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.
The SPAC announced it is merging with medical technology company ProKidney LP, in a deal that values the combined equity of the companies at $2.64 billion.
Amagma Therapeutics announced a licensing agreement with Innovent Biologics for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC Platform.
Based on the success of a joint immuno-oncology antibody collaboration program targeting CD96, GlaxoSmithKline and 23andMe have extended their 2018 collaboration for an additional year.